![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FP Monnet, G Debonnel and C de Montigny
Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
We have reported previously that the high affinity sigma ligand DTG potentiates N-methyl-D-aspartate (NMDA)-induced excitation of pyramidal neurons in the CA3 region of rat dorsal hippocampus. In the present experiments, several selective high affinity sigma ligands have been tested. At low doses, the sigma ligands DTG, JO-1784, JO-1783, AdipG, DnBG, APDQ, BD-737 and (+)-pentazocine dose-dependently enhanced selectively NMDA-induced activation of CA3 pyramidal neurons (with the exception of BD-737 which also presented a late potentiation of the neuronal response to quisqualate). However, at high doses, DTG selectively suppressed the potentiation induced by a low dose of DTG and reduced the NMDA response below base line, presumably due to its low affinity for phencyclidine sites. 2-APHB, a structural analog of DTG devoid of affinity for sigma sites, had no effect on the NMDA response. At low doses that did not by themselves affect the NMDA response, haloperidol, (+)-3-PPP and BMY-14802 reversed DTG- and JO- 1784-induced potentiations of the NMDA response. Spiperone, a butyrophenone with very low affinity for sigma sites, was ineffective in this paradigm. The present data suggest that an important function of sigma receptors could be to modulate the NMDA response in this brain region.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  A. Azzariti, N. A. Colabufo, F. Berardi, L. Porcelli, M. Niso, G. M. Simone, R. Perrone, and A. Paradiso Cyclohexylpiperazine derivative PB28, a {sigma}2 agonist and {sigma}1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther., July 1, 2006; 5(7): 1807 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Anderson, C. R. Jarvis, A. J. Biedermann, C. Molnar, and R. D. Andrew Blocking the Anoxic Depolarization Protects Without Functional Compromise Following Simulated Stroke in Cortical Brain Slices J Neurophysiol, February 1, 2005; 93(2): 963 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. P. Monnet, M. P. Morin-Surun, J. Leger, and L. Combettes Protein Kinase C-Dependent Potentiation of Intracellular Calcium Influx by {sigma}1 Receptor Agonists in Rat Hippocampal Neurons J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 705 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Anderson and R. D. Andrew Spreading Depression: Imaging and Blockade in the Rat Neocortical Brain Slice J Neurophysiol, November 1, 2002; 88(5): 2713 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayashi and T.-P. Su Regulating ankyrin dynamics: Roles of sigma-1 receptors PNAS, January 5, 2001; (2001) 21413698. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hayashi, T. Maurice, and T.-P. Su Ca2+ Signaling via sigma 1-Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca2+ Concentration J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 788 - 798. [Abstract] [Full Text]
|
|
|
|
|
|
O. Soriani, F. L. Foll, F. Roman, F. P. Monnet, H. Vaudry, and L. Cazin A-Current Down-Modulated by sigma Receptor in Frog Pituitary Melanotrope Cells Through a G Protein-Dependent Pathway J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 321 - 328. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|
|
|
|
|
V. K. Shukla and S. Lemaire N-Methyl-D-aspartate Antagonist Activity of alpha - and beta -Sulfallorphans J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 357 - 365. [Abstract] [Full Text]
|
|
|
|
 |
|
 B.E. Leonard and C.D. Nicholson Sigma ligands as potential psychotropic drugs J Psychopharmacol, January 1, 1994; 8(1): 64 - 65. [PDF]
|
|
|
|
|
|
R. E. Adamec Lasting effects of FG-7142 on anxiety, aggression and limbic physiology in the cat J Psychopharmacol, January 1, 1993; 7(3): 232 - 248. [Abstract] [PDF]
|
|
|
|
|
|
T. Hayashi and T.-P. Su Regulating ankyrin dynamics: Roles of sigma-1 receptors PNAS, January 16, 2001; 98(2): 491 - 496. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
